Evotec has received a US$5m milestone payment from Bristol Myers Squibb following the US Food and Drug Administration’s ...

Mursla Bio has announced a new collaboration with a leading global pharmaceutical company to support biomarker-guided drug ...

Eisai has presented new clinical data from a post-hoc sub-group analysis of the Clarity AD open-label extension for lecanemab ...

Teva Pharmaceuticals has announced new real-world data showing that AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR ...

Adocia has announced the filing of a patent for its new long-acting peptide platform, AdoXLong, aimed at improving treatment options for diabetes and obesity. The French biopharmaceutical company said ...

MSD has announced positive results from its phase 3 CORALreef Lipids trial, showing that enlicitide decanoate, an investigational oral PCSK9 inhibitor, significantly reduced low-density lipoprotein ...

Heidelberg Pharma has reported encouraging progress in its phase 2/2a trial of HDP-101 (INN: pamlectabart tismanitin), its ...

The Christie NHS Foundation Trust has completed a four-month digital transformation project using Netcall’s Liberty Spark to ...

The Cell and Gene Therapy Catapult (CGT Catapult) has highlighted the vital role of advanced therapies in supporting the UK ...

Gastro-resistant mercaptamine, marketed as Procysbi, has been accepted for use within NHS Scotland for the treatment of nephropathic cystinosis – a rare, progressive and life-limiting condition ...

Santhera Pharmaceuticals has announced positive topline results from a long-term analysis of AGAMREE (vamorolone) in patients ...

With a favourable safety profile and consistent activity across tumour types, agenT-797 is now poised to enter phase 2 trials. MiNK believes the therapy could redefine treatment for patients with ...